Genentech has partnered with Pieris Pharmaceuticals to discover, develop and commercialise locally-delivered respiratory and ophthalmology therapies based on Pieris' Anticalin® technology. With the deal, Genentech has committed US$20 M upfront and up to US$1.4 B in additional milestone payments across multiple programmes to Pieris. Pieris’ Anticalin® technology has been the subject of a number of collaborations in recent years, including Servier, AstraZeneca and Seattle Genetics.